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Abstract
Applications of next-generation nucleic acid sequencing technologies will lead to the development of
precision diagnostics that will, in turn, be a major technology enabler of precision medicine.
Terabyte-scale, multidimensional data sets derived using these technologies will be used to reverse
engineer the specific disease networks that underlie individual patients’ conditions. Modeling and
simulation of these networks in the presence of virtual drugs, and combinations of drugs, will identify
the most efficacious therapy for precision medicine and customized care. In coming years the practice
of medicine will routinely employ network biology analytics supported by high-performance
supercomputing.
Introduction and context
In his book, The Innovator’s Prescription,C l a y t o n
Christenson describes a continuum of scientific progress
from intuitive medicine, through empirical or evidence-
based medicine to precision medicine, and describes the
phenomenon of ‘disruptive’ innovation [1]. Precision
medicine is characterized by three essential features: an
understanding of what causes a disease; the ability to
detect the causal factors; and the ability to treat the root
causes effectively. In this essay, we equate understanding
the cause of a disease with the ability to quantitatively
model and simulate the operative disease ‘pathways’ or
signaling networks. Detecting the causal factors will be
defined as measuring the molecular biomarkers that
allow us to analyze the flow of information through
these networks. The ability to treat the root causes means
that we have therapeutic agents that are able to
selectively block or redirect the disease pathways.
Molecular biomarkers may consist of macromolecules
and/or metabolites. Here we will only consider nucleic
acid markers, from microRNAs to whole-genome asso-
ciations. The ability to measure these markers, using
so-called next-generation sequencing (NGS) techno-
logies, is undergoing exponential improvements in
data production rates accompanied by steadily declining
costs [2,3]. These technologies could be ‘disruptive’
technology enablers that change the principles and
practices embodied in many existing molecular diag-
nostic assays [4]. Furthermore, the ability to analyze and
interpret large, multidimensional data sets [5] using
biomedical informatics and systems biology techniques
[6-8] will lead to unprecedented diagnostic precision and
the ability to predict the efficacies of individual drugs
and combination therapies in the clinical care setting.
Diagnostic pathologists will have the central role as
integrators and interpreters of the data.
Major recent advances
Second-generation DNA sequencing
A technical review of current (second-generation)
sequencing and NGS technologies is beyond the scope
of this report but several recent and excellent overviews
are available [2,3,9]. For present purposes, the most
important issues are data characteristics, diagnostic
applications, and costs.
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‘read lengths’; the accuracy of ‘calling’ individual bases in
a sequence ‘read’; and the number of such reads per
operational ‘run’ of a given sequencing technology. Read
lengths are the average numbers of contiguous nucleo-
tidebasesinapolynucleotidesequencethatareproduced
by a particular sequencing instrument. Using current
technologies, read lengths vary from approximately
12-400 bases depending upon the particular technology
[2,3,9]. Error rates and, in particular, error modalities are
also technology-dependent. Errors consist of either
inaccurate base calls, leading to erroneous substitutions
in a sequence (an A for a G, for example), or erroneous
insertions or deletions of one or more bases. Raw base-
callingaccuracy is ontheorder of 98.5-99.5%. To achieve
100% accuracy (which is critical for certain medical
applications), varying degrees of oversampling of the
data is a routine component of sequence data produc-
tion. This oversampling is referred to as ‘coverage’, which
indicates the number of times each base has been
sampled in a sequence. Seven- to twelve-fold redundan-
cies(or‘7-12×coverage’)aretypicalsamplingfrequencies
in current practice. High coverage of diverse samples is
possible because next-generation sequencers produce
hundreds of thousands to tens of millions of reads,
depending on the instrument, in a single operational
cycle (which can last from hours to days).
Estimating the cost of sequencing is an accounting
exercise that must take into consideration the costs of
amortized capital equipment, consumable reagents,
labor, and the operational cycle time – many assump-
tions are necessary to compare the costs of different
technologies. Best estimates range from $1 to $60 per
megabase (1 million bases) [9]. The human genome is
about 3 billion bases, or 3,000 megabases, long. The
current cost of determining one human genome at
10-fold coverage is continuously being revised but is
probably on the order of $100,000. Reducing the per-
genome cost to $10,000 and ultimately to $1,000 has
been a stated goal of the US National Human Genome
Research Institute since 2004 [10] and is also the goal of
a $10 million competition sponsored by the X Prize
Foundation [11]. Several attempts to win this competi-
tion are anticipated within a year [3].
In addition to genome applications, NGS will also
dramatically enhance our ability to analyze transcrip-
tomes. Since the mid-1990s, when they were first
invented, gene expression microarrays have been the
dominant technology for transcriptome analysis. Micro-
array technologies rely on sequence-specific probe
hybridization and fluorescence detection. This is an
analog technology subject to noise from background
fluorescence and cross-hybridization and yields only the
relative abundances of mRNAs. Furthermore, array
design is restricted to known sequence entities and, by
definition, not capable of detecting novel transcripts.
Recent studies have observed that digital gene expression
measurements (that is, actual direct enumeration of
mRNAs) using currently available sequencing technolo-
gies offer significant advantages in resolution and
reproducibility [12]. It should be feasible to use digital
gene expression profiling longitudinally to study the
natural history of disease as well as monitor response to
therapy (see below).
Network biology
There are a number of different approaches to interpret-
ing large sequencing datasets and, increasingly, these fall
within the realm of systems or network biology [6-8].
Two contrasting approaches for unraveling the behavior
of underlying genetic circuits and biochemical pathways
are: (a) the curation of well-known biological pathways
from the literature and conversion to descriptive visual
displays depicting them as maps to visualize molecular
profile changes in their context [for example, Kyoto
Encyclopedia of Genes and Genomes (KEGG) [13],
Ingenuity Systems [14], and GeneGo Metacore [15]
pathway analysis]; and (b) the construction of systems
ofdifferential equationsthatmodelthetimeevolutionof
gene products and their connection to phenotypic
changes [16-18]. While many of these efforts are
impressive and in some rare cases have the ability to
makenon-intuitivepredictionssupportedbyexperiment,
these approaches address only a tiny fraction of the total
possiblecircuitryofhumanbiologyanddisease.Classical
engineeringsolutionsdependonacompleteandaccurate
blueprint ofthesystem[19].Blackbox modelsalsowork,
provided the inputs and outputs are robustly validated.
Wearestillfarfromhavingcomparableblueprintsfor the
pathophysiologies of disease: connections are still miss-
ing, and systematic measurements to parameterize and
otherwise validate models are still hard to make. But
some exciting progress has been made.
Sieberts and Schadt [20] pioneered the creation and
application of methods that linked genetic alterations to
transcriptional changes and physiological outcomes in
a genetic cross of two inbred mouse strains, one with a
propensity for obesity and diabetes, and the other with
a genetic resistance to obesity and diabetes. Here the
genetic diversity acted as the ‘perturbation’ or ‘driver’ that
allowed correlation between various components to be
interpreted as ‘causal’ network interactions. Bayesian
network inference algorithms applied to these well-
designed data sets revealed a complex interconnected
circuitry of several hundred genes that drive the low
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triglyceride metabolism, and body mass index of these
mice that was subsequently validated in a large human
cohort [21,22]. This work led to the discovery of several
novel drug targets and drug candidates (E Schadt,
personal communication). Groups such as ours have
developed technology that formalizes these approaches
and applies them to the discovery of biomarkers and
drug targets. The key aspects of these methods and their
growing success and future challenges include: the use of
genetic variation and/or drug perturbation combined
with transcriptional or other molecular profiling changes
and clinical outcomes to go beyond correlation to extract
causal interactions; the use of large-scale supercomput-
ing involving thousands or tens of thousands of
processors to score billions of possible network frag-
ments and evaluate billions of system-wide network
hypotheses that can best explain the data; having a
sufficient number of patients or biological samples of
appropriate genetic diversity and/or the use of appro-
priate animal models as surrogates for human diseases.
Future directions
Sequence-based diagnostic applications
Based upon current research applications of second-
generation sequencing [5,9] and a knowledge of current
molecular diagnostic methods and their uses [4], many
future diagnostic applications of NGS can be anticipated.
For example, sequencing is being used for polymor-
phism and mutation detection and cataloging, measure-
ment of copy number variation and other structural
variations such as insertions, deletions, and gene
rearrangements, epigenetic analysis of DNA methylation
and chromatin remodeling, and digital transcriptional
profiling and metagenomic analysis of heterogeneous
microbial populations [5,9]. It is likely that various
applications of NGS technology will eventually supplant
a wide range of classical techniques used in clinical
Figure 1. Workflow for precision diagnostics in personalized medicine
Processes in the top row depict a patient interacting with clinical specialists. The middle and bottom rows depict the largely automated processes that will
occur in the pathology department. The natures of the individual processes are as indicated in the key below the figure. The large arrowheads depict control
transfers of biospecimens and data between clinical departments and pathology. Pathology reports of the future will be interactive, containing links to
underlying databases and parameter sets that clinical teams can use to perform their own simulations for developing a customized treatment plan for the
individual patient.
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sis of cancer and many non-neoplastic diseases, human
leukocyte antigen (HLA) typing and infectious disease
and include cytogenetics, PCR-based assays, Southern
blot analysis, analog microarray technologies, and
microbiology [4,23]. Unlike the current spectrum of
labor-intensive, heterogeneous methods, NGS diagnos-
tics will be completely automated. Furthermore, the
ability of a single technology to produce multilayer,
integratable data will enable precision diagnostics and
the medical applications of network biology.
Diagnostic and therapeutic applications of network
biology
We are still in the discovery and validation phases of
network biology but feel confident that over the next
10 years we will have elucidated and modeled a number
of disease pathways to the point where realistic in silico
simulations of therapeutic interventions will not only be
a routine process for drug and biomarker discovery but
also useful for personalized medicine. We envision the
following scenario (Figure 1) in which pathologists will
extend their traditional role as integrators of data to
diagnose and classify disease to become modelers of
disease processes [24] who will provide clinicians and
their patients with customized care information and
therapeutic recommendations. Customized care infor-
mation should include the specific aberrantly regulated
genes, RNAs, and proteins that are responsible for
driving the disease process, the number of signaling
circuits that are involved, and the drug targets that they
contain. Therapeutic recommendations should include
the drug or combination that is predicted to be most
effective in a particular patient, the best biomarkers to
monitor response to therapy – that is, the additional
diagnostic tests that are the most valuable surrogate
markers for predicting treatment outcomes – and, if the
patient becomes resistant to initial therapy, the compen-
satory or parallel pathways that need to be drugged.
The pathology report of the future will provide precision
diagnoses that are at the core of personalized medicine
and will be an interactive software tool for clinical teams
to design a customized care regimen and monitor its
efficacy during treatment.
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